Congress delegates sweeping biotech export controls without defining who's banned
S. 3452 — Biological Intellectual Property Protection Act of 2025 · Filed by Tom Cotton (R-AR) · 3 cosponsors · Introduced Dec 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the U.S. government to issue export licenses for synthetic DNA and RNA sequences being sent to foreign countries deemed adversarial (particularly China). It frames this as a national security measure to prevent intellectual property theft and military modernization by hostile powers, citing China's laws requiring citizens to support state security objectives.
Why we flagged it
The bill's core function is to impose licensing requirements on synthetic DNA/RNA exports to adversarial nations, framed as intellectual property and national security protection. However, the actual mechanism—delegating broad authority to the executive to define 'foreign entities of concern' and determine what sequences require licensing—is regulatory rather than legislative.
What the text implies
- The bill grants the executive branch (via the Commerce Department) sweeping discretion to define 'foreign entity of concern' without legislative definition, potentially capturing academic institutions, international collaborators, and private companies with no clear appeal process.
- Synthetic DNA/RNA licensing could create a de facto chokepoint on biotech research collaboration, potentially slowing U.S. innovation if export reviews are slow or overly restrictive, harming the very U.S. biotech sector the bill claims to protect.
The full analysis lists 5 implications of this text.
Who stands to gain
large pharmaceutical and biotech companies with proprietary synthetic biology IP; defense contractors with biotech divisions; companies with existing export compliance infrastructure